Advisors Capital Management LLC Raises Holdings in Zoetis Inc. $ZTS

Key Points

• Advisors Capital Management LLC increased its holdings in Zoetis Inc. by 2.4%, owning 135,077 shares worth approximately $22.24 million at the end of the first quarter.
• Multiple large institutional investors, including Nuveen LLC and Mackenzie Financial Corp, have significantly increased their stakes in Zoetis during the first quarter, driving institutional ownership to 92.80%.
• Zoetis reported strong quarterly earnings with an EPS of $1.76, beating analyst estimates, and set a FY 2025 guidance of 6.300-6.400 EPS as revenue grew 4.2% year-over-year.

Advisors Capital Management LLC increased its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 2.4% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 135,077 shares of the company's stock after acquiring an additional 3,105 shares during the period. Advisors Capital Management LLC's holdings in Zoetis were worth $22,241,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the company. Nuveen LLC acquired a new stake in shares of Zoetis in the first quarter valued at $616,375,000. Sarasin & Partners LLP acquired a new stake in Zoetis in the first quarter valued at about $339,111,000. Mackenzie Financial Corp lifted its position in Zoetis by 4,158.3% in the first quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company's stock valued at $300,481,000 after purchasing an additional 1,782,110 shares during the period. GAMMA Investing LLC lifted its position in shares of Zoetis by 14,731.3% during the 1st quarter. GAMMA Investing LLC now owns 1,759,285 shares of the company's stock valued at $289,666,000 after acquiring an additional 1,747,423 shares during the period. Finally, Polen Capital Management LLC lifted its position in shares of Zoetis by 17.6% during the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company's stock valued at $1,448,401,000 after acquiring an additional 1,313,653 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ZTS has been the subject of several research reports. Argus restated a "buy" rating and set a $190.00 price objective on shares of Zoetis in a research report on Tuesday. Leerink Partnrs cut shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Piper Sandler boosted their price objective on shares of Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a research note on Monday, August 11th. Leerink Partners cut shares of Zoetis from an "outperform" rating to a "market perform" rating and decreased their price target for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Finally, Stifel Nicolaus cut shares of Zoetis from a "buy" rating to a "hold" rating and decreased their price objective for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Five research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $200.88.

Zoetis Stock Performance

NYSE:ZTS opened at $149.45 on Thursday. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The firm has a 50-day moving average of $152.70 and a two-hundred day moving average of $157.56. The stock has a market cap of $66.24 billion, a P/E ratio of 25.72, a PEG ratio of 2.40 and a beta of 0.89. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. The company had revenue of $2.46 billion during the quarter, compared to analysts' expectations of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm's revenue for the quarter was up 4.2% on a year-over-year basis. During the same period in the prior year, the company posted $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.